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The aim of this study was to characterize the cerebrospinal fluid (CSF) prion protein (PrP) of healthy
and naturally scrapie-affected sheep. The soluble form of CSF PrPC immunoblotted with an
anti-octarepeat and an anti-C terminus mAb showed two isoforms of approximately 33 and 26 kDa,
corresponding to the biglycosylated and unglycosylated isoforms of brain PrPC. Neither the mean
concentration nor the electrophoretic profile of CSF PrP differed between healthy and scrapie-
affected sheep, whereas a slightly increased resistance of CSF PrP to mild proteolysis by
proteinase K was evident in the CSF of scrapie-affected sheep. No difference in susceptibility to
proteolysis was observed between the twoARR and VRQgenetic variants of the purified prokaryote
recombinant PrP. It was concluded that the physicochemical properties of PrPC in theCSF could be
altered during scrapie and that these changes might reflect the physiopathological process of prion
disease.
Prion diseases are characterized by neuropathological
changes confined to the central nervous system and cerebral
deposition of a partially proteinase K-resistant isoform
(PrPSc) of the host-encoded cellular prion protein (PrPC),
which is highly expressed in the brain. As cerebrospinal fluid
(CSF) is the extracellular fluid that bathes the brain cells, the
characteristics of PrPC in this medium might reflect the
physiopathological process affecting PrPC in the brain.
Indeed, PrP levels in the CSF might be altered by trapping of
PrP in the PrPSc aggregates accumulated in the extracellular
spaces. Alternatively, PrPSc molecules released by extra-
cellular aggregates might join the interstitial fluid that is
postulated to leak into the CSF. Different techniques have
been developed to detect PrPSc in the CSF, but none has
given consistent results (Bieschke et al., 2000; Wong et al.,
2001). Although firm evidence of prion infectivity in the
CSF is still lacking, studies based on experimental
transmission suggest that the infectivity of CSF is low
(Brown et al., 1994).
We hypothesized that prion diseases might be associated
with modifications of the CSF PrP concentration and/or
biochemical properties that could be of physiopathological
and diagnostic relevance. Ovine scrapie is a model of natural
prion disease for which the impact of the prion protein gene
(PRNP) polymorphism at positions 136, 154 and 171 on
disease susceptibility is well documented. The V136R154Q171
(VRQ) and ARR alleles have consistently been associated
with the highest susceptibility or natural resistance to the
clinical disease, respectively (Hunter et al., 1997; Elsen et al.,
1999; Baylis et al., 2004), although atypical scrapie strain(s)
can naturally infect sheep harbouring the so-called resistant
PrP genotype (Le Dur et al., 2005).
Changes in PrPC concentrations and/or biochemical
features in the CSF of scrapie-affected sheep might reflect
those occurring during spontaneous prion disease. Our aim
was to evaluate the influence of scrapie on CSF PrP
concentrations, electrophoretic profile and sensitivity to
mild proteolysis by proteinase K (PK). Possible genetic
involvement was examined by comparing the PK sensitiv-
ities of ARR and VRQ genetic variants of the purified
recombinant ovine PrP expressed in Escherichia coli.
Table 1 gives the characteristics of the 13 clinically scrapie-
affected and 12 healthy sheep used in the different
experiments. PrP genotypes at codons 136, 154 and 171
were determined from blood samples (Scanelis, Toulouse,
France). Scrapie diagnosis was confirmed by histological
examination (neuronal and neuropil vacuolation in the
grey matter, and gliosis) of the brainstem (obex).
Immunohistochemical tests were performed in healthy
sheep with no detectable histopathological lesions using a
method described previously (Andre´oletti et al., 2000) to
check for the absence of PrPSc deposition in the cerebellum,
obex and cerebral cortex (O. Andre´oletti, personal com-
munication) and exclude possible atypical forms of scrapie.
All experimental procedures were performed in accordance
with French legal requirements regarding the protection of
laboratory animals. Lumbar CSF obtained by direct
puncture was centrifuged for 10 min at 1500 g and stored
at 220 uC until assayed.
The electrophoretic profile of CSF PrP and sensitivity to
mild proteolysis by PK were characterized by immunoblot-
ting with two anti-PrP mAbs: Pc248, directed against the
octarepeat region (Moudjou et al., 2001), and BAR224, an
anti-C terminus mAb recognizing residues 141–151 (Morel
et al., 2004). CSF samples were concentrated fivefold
using a centrifugal device with a molecular mass cut off of
10 kDa (Nanosep; Pall Life Sciences). Approximately 15 mg
protein from concentrated CSF and 6 mg protein from a
20% brain homogenate in sucrose buffer from a healthy
sheep were separated by SDS-PAGE using a Bio-Rad
apparatus. Protein transfer was carried out onto a
nitrocellulose membrane using a Minigel Transblot Cell
System (Bio-Rad). The membrane was incubated with
Pc248 or BAR224 anti-PrP mAbs at a 1 : 5000 dilution and
the blots were visualized by enhanced chemiluminescence
(Amersham Pharmacia Biotech) using goat anti-mouse IgG
coupled to peroxidase (Amersham) at a 1 : 2000 dilution as
the secondary antibody. Signal specificity was tested by
incubating the membrane with the anti-mouse secondary
antibody alone.
A deglycosylation experiment was also carried out to check
that the protein bands that were immunodetected by mAb
Pc248 in the ovine CSF corresponded to PrP glycoforms.
Brain homogenate or unconcentrated CSF samples were
treated with 2 U N-glycosydase F (Roche) and incubated
overnight at 37 uC in the presence of 2% Nonidet P40 and
1% SDS. Samples were then diluted in Laemmli sample
buffer and analysed by Western blotting.
The fivefold-concentrated CSF samples were treated with
different concentrations of PK for 1 h at 37 uC. Proteolysis
was stopped by adding SDS-sample buffer and heating for
5 min at 95 uC.
An ELISA approach was also developed to quantify and
compare the PK sensitivities of PrP from the CSF of healthy
and scrapie-affected sheep and those of genetic variants of
the prokaryote recombinant ovine PrP (Rezaei et al., 2000).
Solutions (20 ng ml21) of the VRQ and ARR variants of the
prokaryote recombinant ovine PrP were prepared in 0?1 M
phosphate buffer containing 1 mg BSA ml21, 0?15 M NaCl
and 0?01% NaN3. PK was added at final concentrations
ranging from 0?125 to 3 mg ml21 in CSF and from 0?004
to 0?125 mg ml21 in the recombinant protein solutions.
Table 1. Characteristics of the sheep used in the different experiments
Code Breed* Gender Genotype Status ExperimentD
4680 M Female ARH/ARH Healthy ELISA
8887 M Female ARQ/ARH Healthy WBPc248
9397 M Female ARR/ARQ Healthy ELISA; WBPc248
R027 M Female ARR/ARQ Healthy ELISA; WBPc248
416 M Female ARQ/ARQ Healthy ELISA; WBPc248
083 M Female ARQ/AHQ Healthy ELISA; WBPc248
5969 M Female ARQ/ARH Healthy WBPc248 (PK)
30096 R Male ARR/ARR Healthy ELISA; WBPc248 (PK); WBBAR224 (PK); deglyc.
30104 R Male ARR/ARR Healthy ELISA; WBPc248 (PK); WBBAR224 (PK)
30307 R Male ARR/ARR Healthy ELISA; WBPc248 (PK); WBBAR224 (PK)
30308 R Male ARR/ARR Healthy ELISA; WBPc248 (PK); deglyc.
30152 R Male ARR/ARR Healthy WBBAR224
5356 M Female ARQ/ARQ Scrapie ELISA; WBPc248
9144 M Female ARH/VRQ Scrapie ELISA; WBPc248
1018 M Female ARQ/ARQ Scrapie ELISA
1017 M Female ARQ/ARQ Scrapie ELISA
0857 M Female ARQ/VRQ Scrapie WBPc248
487 M Female ARQ/ARQ Scrapie WBPc248 (PK)
0830 M Female ARQ/ARH Scrapie WBPc248
0767 M Female ARQ/ARQ Scrapie WBPc248
0957 M Female ARQ/ARH Scrapie WBPc248
30028 R Male VRQ/VRQ Scrapie ELISA; WBPc248 (PK); WBBAR224; deglyc.
30200 R Male VRQ/VRQ Scrapie ELISA; WBPc248 (PK); WBBAR224 (PK); deglyc.
30376 R Male VRQ/VRQ Scrapie ELISA; WBPc248 (PK); WBBAR224 (PK)
30390 R Male VRQ/VRQ Scrapie WBPc248 (PK)
*M, Manech Redface; R, Romanov.
DWB, Western blotting: the anti-PrP mAb used (Pc248 or BAR224) is indicated; PK is shown in parentheses when a PK test was performed;
deglyc., deglycosylation.
Reactions were carried out at 37 uC for 1 h, stopped with
4 mM stopper (Pefabloc; Roche) and analysed by ELISA
using anti-PrP antibodies SAF34 and 12F10-AchE (SPI-
BIO). The whole CSF protein concentration was determined
by Bradford’s method, using a Bio-Rad protein assay kit.
Results were reported as mean±SEM. Statistical analyses
were performed using SYSTAT 8.0 (SPSS Inc.). Proteolysed
PrPC concentrations expressed as a percentage of the PrPC
concentration in untreated CSF were determined from the
difference between the PrPC concentration in untreated CSF
and uncleaved PrPC concentrations evaluated by ELISA. The
relationship between PK and the proteolysed PrP fraction
was determined by plotting the proteolysed PrP fraction
against the PK concentrations. The data were fitted by
applying the sigmoidal Hill model, as described previously
(Toutain, 2002). The parameters Emax (100%), EC50
(median effective concentration; potency) and Q (slope)
were evaluated using a non-linear least-squares regression
program and the effect of scrapie on mean parameters was
analysed by Student’s t-test.
The effect of the genetic variant of the prokaryote
recombinant PrP on uncleaved PrP concentrations was
analysed using a two-factor ANOVA (variant and PK
concentration effects).
The CSF PrPC profile of healthy sheep on a Western blot
probed with mAb Pc248 (Fig. 1a) showed two major bands
migrating at approximately 33 and 26 kDa, at about the
same level as the biglycosylated and unglycosylated isoforms
of brain PrPC, respectively. CSF treatment with N-
glycosydase F generated two immunoreactive bands, one
major band of 26 kDa, corresponding to the full-length
non-glycosylated PrPC isoform, and another less reactive
band with a reduced molecular mass of 23 kDa (Fig. 1b). As
this band was recognized by an anti-octarepeat mAb
(Pc248), it might correspond to a PrP C-terminal truncated
form, as also observed in fluids from the genital tracts of
sheep (Ecroyd et al., 2004). On the Western blot probed
with mAb BAR224, the PrP profile in the CSF showed one
thin, specific band migrating approximately the same
distance as the 33 kDa biglycosylated PrPC from the brain
(Fig. 1c). The major band detected in CSF at 27 kDa
corresponded to the endogenous IgG light chains cross-
reacting with the secondary antibody, as it was system-
atically detected in the absence of primary antibody and
disappeared in non-reducing conditions. This band was not
detected in the control brain sample (Fig. 1c). A low affinity
of BAR224, in comparison with Pc248 mAb, for PrP could
explain the PrP profile obtained with mAb BAR224. The
immunoreactive PrP profiles for the two anti-PrP antibodies
did not differ between healthy and scrapie-affected sheep
(Fig. 1a and c).
On the Western blot probed with mAb Pc248, PrPC was
completely digested by treatment of CSF with 5 mg P Kml21
in both healthy and scrapie-affected sheep (Fig. 1d).
Nevertheless, the fraction of PrP that remained uncleaved
Fig. 1. Representative Western blots of PrP in CSF samples
from scrapie-affected and healthy sheep. A brain homogenate
from a healthy ewe was included for comparison. (a, b)
Electrophoretic profile of CSF PrP detected by Western blotting
with anti-PrP mAb Pc248 and effect of N-glycosydase F (N-Gly
F) treatment on CSF PrP profile. (c) Electrophoretic profile of CSF
PrP immunodetected with (+) or without (”) anti-PrP mAb
BAR224 in reducing (b-mercaptoethanol; b-SH) (+) or in non-
reducing (”) conditions. The arrow indicates the biglycosylated
form of PrP. Note that the reactivity of mAb BAR224 is enhanced
in non-reducing conditions. (d, e) PK sensitivity of CSF PrP.
Samples were incubated with or without PK at final concentrations
of 0?5, 2 or 5 mg ml”1 (d) or 1, 10 or 50 mg ml”1 (e).
Immunoblots were visualized with anti-PrP mAb Pc248 (d) or with
anti-PrP mAb BAR224 (e). The sizes of the molecular mass mar-
kers (New England Biolabs) are given on the right of each panel.
with 0?5 and 2 mg PK ml21 was greater in the CSF of
scrapie-affected sheep than in that of healthy ones. When
probed with the anti-C terminus mAb BAR224, a positive
PrP signal was still observed followed digestion with up to
1 mg PK ml21 in scrapie (Fig. 1e) but not in healthy CSF.
This signal disappeared in both healthy and scrapie CSF after
treatment with 10 mg PK ml21 (Fig. 1e). The faint band
detected after treatment with 50 mg PK ml21 might corre-
spond to PK, which is known to give a faint positive signal
with ECL reagents.
Physiopathological status had no effect on whole-protein
concentrations in the CSF (176?7±29?6 vs 232?7±
62?5 mg ml21 in nine healthy vs seven scrapie-affected
sheep, P>0?05). The PrP isoform monitored by ELISA
might correspond to uncleaved PrP, as SAF34, an anti-
octarepeat region mAb, was used for capture in the ELISA
experiments. The mean CSF PrP concentration of scrapie-
affected sheep (10?9±1?3 ng ml21, n=7) did not differ
from that of healthy sheep (9?6±0?81 ng ml21, n=9).
Fig. 2 illustrates the relationship between the fraction of
proteolysed PrP and PK concentrations in the CSF of
representative healthy and scrapie-affected sheep and the
corresponding fitted curves. The mean EC50 value of PK
determined from the CSF of scrapie-affected sheep was
greater than that evaluated from the CSF of healthy sheep
(0?51±0?05 vs 0?35±0?05 mg ml21, P<0?05), indicating
that the relative resistance of CSF PrP to mild proteolysis
by PK was increased in scrapie-affected sheep. The con-
centration of the two ARR and VRQ genetic variants of
the prokaryote recombinant PrP decreased exponentially
with PK concentration, reaching undetectable values at
0?125 mg ml21, and did not differ, whatever the PK con-
centration (data not shown).
CSF PrP concentrations from scrapie-affected sheep did not
differ from those of healthy ones. As observations in
Alzheimer’s disease have shown that the level of soluble
amyloid decreases whereas the amount of protease-resistant
b-amyloid increases (Weller, 1998), one might have
expected a fall in soluble PrP levels in the CSF of scrapie-
affected sheep resulting from the formation of amyloid
deposits. In our study, mature CSF PrP represented only
0?01% of the total proteins, i.e. a ratio within the same range
as that reported for PrPC in the nervous tissue (Moudjou
et al., 2001). PrPC in the CSF could originate from the brain,
being released by cells lining the ventricular system
(ependyma, choroid plexus) and/or by neuronal cells in
the interstitial fluid, the contents of which are postulated to
leak into the CSF (Weller, 1998). However, it cannot be
excluded that a portion of the PrPC might be transported
from the blood to the CSF by pinocytosis or specific carrier
mechanisms at the level of the choroid plexus. Indeed, a
soluble form of PrPC was detected in ovine plasma (data not
shown) and 80% of the proteins found in the CSF were
shown to originate from the systemic circulation (Green,
2002). This is important for estimating the risk of
transmission of prion disease via blood transfusion, as
PrPSc transported from the blood to the CSF could diffuse
across the ependyma lining the ventricular system into the
brain tissue. Banks et al. (2004) have shown that the murine
scrapie prion protein can cross the blood–CSF barrier and
enter the brain CSF compartment.
The PrP isoforms monitored in the CSF were PK sensitive
and no intermediate degradation products could be
evidenced by immunoblotting. When probed with the
anti-C terminus mAb BAR224, the specific signal was
abolished in CSF from healthy and scrapie-affected sheep at
PK concentrations of about 10 mg ml21, corresponding to
5 mg (mg protein)21, i.e. the same PK concentration range
used for diagnostic purposes (Baron et al., 1999). These
results strengthen the hypothesis that PrPres is absent in the
CSF of scrapie-affected sheep.
Our results also showed that PrP in the CSF of scrapie-
affected sheep was ‘more resistant’ than PrP from the CSF of
healthy sheep to proteolysis by PK. Although slight, this
effect was robust and reproducible. Indeed, it was demon-
strated both by immunoblot with two anti-PrP mAbs that
bind very distinct regions of the protein and by ELISA. This
differential PK effect could originate from intrinsic varia-
tions in the PK sensitivity of the protein variants, as all
scrapie-affected sheep except four were homozygous for
VRQ or ARQ alleles encoding susceptible variants of PrP,
whilst more than half of the healthy sheep carried one copy
of the ARR or AHQ alleles conferring resistance.
Buschmann et al. (1998) have shown that the PrPC of
brain homogenates of homozygous ARR/ARR healthy sheep
display a higher sensitivity to PK than the PrPC of healthy
ARQ/ARQ sheep. Such a difference was also observed when
the two ARR and VRQ variants of the prokaryote
recombinant ovine PrP were compared (Rezaei et al.,
2000). In our experimental conditions, the recombinant PrP
protein was highly sensitive to PK and no difference in
sensitivity to PK was evidenced between the two genetic
variants. This suggests that the higher resistance of PrP from
Fig. 2. Semi-logarithmic plot of observed and fitted fraction
(solid line) of CSF PrP proteolysed as a function of PK con-
centrations in a representative healthy (%) and a representative
scrapie-affected sheep (&). EC50 is the PK concentration
required for 50% proteolysis.
the CSF of scrapie-affected sheep may not result from PRNP
gene polymorphism. Instead, the slower decrease in
uncleaved PrP with increasing PK concentrations in the
CSF of scrapie-affected sheep could reflect a partial change
in the physicochemical properties of PrP, i.e. a transitional
state of PrP towards a pathological isoform in scrapie-
affected sheep, which could be of physiopathological
significance. In agreement with this hypothesis, Safar et al.
(1998) have suggested the existence of an intermediate
protease-sensitive isoform of the prion protein formed
during the process of transconformation of PrPC into PrPSc.
In conclusion, we have shown that a soluble PrP is present as
a protease-sensitive isoform in the CSF of healthy and
scrapie-affected sheep. The PrP concentrations in CSF and
the electrophoretic profile were unaffected by the disease.
However, our results suggest that the biochemical feature of
PrP, i.e. its relative resistance to proteolysis, is slightly
modified in scrapie-affected sheep.
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